Unexpected behavior of neutrophils unveiled by researchers at Stanford University could lead to a new type of immunotherapy to treat cancer. Although various studies have suggested that these cells are harmful due to their immunosuppressive characteristics, the scientists saw in them an opportunity to redirect them and eliminate tumors. Read More
Roquefort Therapeutics plc's ROQ-A1 and ROQ-A2 Midkine (MDK) antibody programs, targeting metastatic breast cancer and metastatic lung cancer, have successfully demonstrated in vivo safety in preclinical development programs conducted by cancer research groups. Read More
Researchers from Curacle Co. Ltd. and Yonsei University have published preclinical data for the endothelial dysfunction blocker CU06-1004 from studies assessing it in models of retinal vascular disease. Read More
Lapix Therapeutics Inc. has announced the successful outcome of its pre-IND meeting request with the FDA to achieve alignment on the company's IND-enabling plan for LPX-TI641, being developed for neuro-autoimmune indications such as multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), and myelin oligodendrocyte glycoprotein antibody disease (MOGAD). Read More
Researchers from Wenzhou Medical University and affiliated organizations have reported the discovery and preclinical evaluation of novel anti-inflammatory compounds. Synthesis and optimization of a new series of 1-(4-(benzylsulfonyl)-2-nitrophenyl) derivatives resulted in the identification of compound [I] as the lead candidate. Read More
Herophilus Inc. is conducting in vivo studies of lead candidate HRP-12975, a small-molecule therapy for Rett syndrome, with funding from the Rett Syndrome Research Trust. The company is generating efficacy and safety data with HRP-12975 using genetic mouse models of Rett syndrome. Read More
Exegi Pharma LLC has received FDA clearance of its IND application for EXE-346, allowing the company to initiate a clinical trial to evaluate EXE-346 in the management of excessive stool frequency in patients with an ileal pouch-anal anastomosis (IPAA, J-Pouch). Read More
Shanghai University of Traditional Chinese Medicine and Vestlandets Innovasjonsselskap AS (VIS) have disclosed bufalin derivatives acting as androgen receptor antagonists reported to be useful for the treatment of prostate cancer. Read More
Sana Biotechnology Inc. has received FDA clearance of its IND application to initiate a first-in-human study of SC-291 in patients with various B-cell malignancies. Initial clinical data from the study are expected later this year. SC-291 is a CD19-targeted allogeneic chimeric antigen receptor (CAR) T-cell therapy developed using Sana's hypoimmune platform. Read More
Medshine Discovery Inc. has synthesized dimethyl-substituted thiazololactam compounds acting as mitogen-activated protein kinase 3 (MAPK3; ERK1) and/or (MAPK1; ERK2) inhibitors reported to be useful for the treatment of cancer. Read More
Heart failure still remains a leading cause of death worldwide. Improving risk stratification and prognostic analysis tools is required to aid in the management of the disease. Read More
Janssen Pharmaceutica NV has identified 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, viral hepatitis, diabetes, immunological, inflammatory, neurological, cardiovascular and metabolic disorders. Read More
Genkore Inc. has entered into a strategic research collaboration with a U.S.-based biopharma company for the development of in vivo gene editing therapies. Read More
Centessa Pharmaceuticals plc has received clearance of its IND application from the FDA to initiate a first-in-human phase I/IIa trial of LB-101 for the treatment of solid tumors. Read More
Astrazeneca AB and Mitsubishi Tanabe Pharma Corp. have divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of liver, autoimmune and inflammatory bowel disease, inflammation, respiratory, cardiovascular and renal disorders. Read More
HBM Alpha Therapeutics Inc. has completed seed financing to advance its lead programs, novel antibody therapies to treat congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS). Read More
Androgen deprivation therapy (ADT) is still the main treatment option for locally advanced and metastatic prostate cancer (PCa); however, most patients receiving ADT develop resistance to treatment and relapse, with a more aggressive form of cancer, castration-resistant prostate cancer (CRPC). Read More
